Villarroya Francesc, Peyrou Marion, Giralt Marta
Departament de Bioquímica i Biomedicina Molecular, Departament de Bioquímica i Biomedicina Molecular, Facultat de Biologia, Universitat de Barcelona, Avda Diagonal 643, Barcelona, Catalonia, 08028, Spain.
Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.
Curr Obes Rep. 2025 Sep 2;14(1):67. doi: 10.1007/s13679-025-00660-w.
This review summarizes recent evidence highlighting the specific role of adipose tissue in the systemic effects of incretin agonist-based drugs used in the treatment of obesity.
The development of incretin agonist-based drugs has achieved unprecedented success in the pharmacological treatment of obesity and the improvement of obesity-related comorbidities. While initially shown to significantly reduce adipose tissue through decreased food intake, incretin-based therapy is also increasingly reported to alter the properties of adipose tissue. Recent experimental and human studies indicate that these anti-obesity drugs induce significant changes in the metabolism and inflammatory state of adipose tissue, while also promoting its thermogenic plasticity. The direct and indirect actions of incretin-based anti-obesity drugs, which modify the properties of adipose tissue, are emerging as key contributors to the systemic health benefits of these treatments.
本综述总结了近期的证据，突出了脂肪组织在用于治疗肥胖症的肠促胰岛素激动剂类药物的全身效应中的特定作用。
基于肠促胰岛素激动剂的药物开发在肥胖症的药物治疗以及肥胖相关合并症的改善方面取得了前所未有的成功。虽然最初显示通过减少食物摄入量可显著减少脂肪组织，但越来越多的报道称基于肠促胰岛素的疗法也会改变脂肪组织的特性。最近的实验和人体研究表明，这些抗肥胖药物会引起脂肪组织代谢和炎症状态的显著变化，同时还会促进其产热可塑性。基于肠促胰岛素的抗肥胖药物改变脂肪组织特性的直接和间接作用，正成为这些治疗对全身健康有益的关键因素。
